



NDA 050805/S-002

SUPPLEMENT APPROVAL

Galderma Laboratories, L.P.
Attention: Richard Almond
Manager, Regulatory Affairs
14501 N. Freeway
Fort Worth, TX 76177

Dear Mr. Almond:

Please refer to your supplemental new drug application dated June 17, 2009, received June 18, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Oracea (doxycycline, USP) Capsules, 40 mg.

We acknowledge receipt of your submissions dated August 24, 2009, and April 29, 2010.

This supplement provides for the revision of the Oracea Capsules full prescribing information to meet the new labeling content and format requirements for human prescription drug and biological products according to 21 CFR 201.56(d) and 201.57.

We also refer to our teleconference held on April 28, 2010, where we acknowledged that changes to your carton and container labels approved on May 26, 2006, are not required at this time.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling text and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
5600 Fishers Lane, Room 12B05
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tamika White, Regulatory Project Manager, at (301) 796-0310.

Sincerely,

{See appended electronic signature page}

Susan J. Walker, M.D., F.A.A.D.
Director
Division of Dermatology and Dental Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure
Content of Labeling

Application
Type/Number

Submission
Type/Number

Submitter Name

Product Name

NDA-50805

SUPPL-2

GALDERMA
LABORATORIES
LP

ORACEA (DOXYCYCLINE
MONOHYDRATE)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUSAN J WALKER
05/13/2010